ArticleJournal of the National Cancer Institute2017
Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.
Article in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Predictive value of machine learning for breast cancer recurrence: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- Evolution of Breast Cancer Recurrence Risk Prediction: A Systematic Review of Statistical and Machine Learning-Based Models.JCO clinical cancer informatics · 2023Pooled it
- Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.International journal of cancer · 2023Pooled it
- Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.International journal of cancer · 2023Pooled it
- Predictive value of radiomics-based machine learning for the disease-free survival in breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Prognostic model for predicting recurrence in breast cancer patients in Saudi Arabia.Scientific reports · 2025Article
- The functional TNF-αBreast cancer research and treatment · 2025Article
- A novel machine learning prediction model for metastasis in breast cancer.Cancer reports (Hoboken, N.J.) · 2024Article
- Evaluation of Predict, a prognostic risk tool, after diagnosis of a second breast cancer.JNCI cancer spectrum · 2023Article
- Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization.European journal of breast health · 2023Article
- Machine learning survival models trained on clinical data to identify high risk patients with hormone responsive HER2 negative breast cancer.Scientific reports · 2023Article
- PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants.NPJ breast cancer · 2023Article
- A Comparison between the Online Prognostic Tool PREDICT and myBeST for Women with Breast Cancer in Malaysia.Cancers · 2023Article
- Analyzing breast cancer invasive disease event classification through explainable artificial intelligence.Frontiers in medicine · 2023Article
- Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence.Frontiers in endocrinology · 2023Review
- Development of Predictive Models for Survival among Women with Breast Cancer in Malaysia.International journal of environmental research and public health · 2022Article
- Preoperative Routine Laboratory Markers for Predicting Postoperative Recurrence and Death in Patients with Breast Cancer.Journal of clinical medicine · 2021Article
- Article
- A Clinical Decision Support System for Predicting Invasive Breast Cancer Recurrence: Preliminary Results.Frontiers in oncology · 2021Article
- Large-scale tumor-associated collagen signatures identify high-risk breast cancer patients.Theranostics · 2021Article
Corrections and comments
- Commented on by
- Commented on byResponse.2017
Authors and funding
14 authors.
Funding
Abstract
Background: In this study, we developed integrative, personalized prognostic models for breast cancer recurrence and overall survival (OS) that consider receptor subtypes, epidemiological data, quality of life (QoL), and treatment. Methods: A total of 15 314 women with stage I to III invasive primary breast cancer treated at The University of Texas MD Anderson Cancer Center between 1997 and 2012 were used to generate prognostic models by Cox regression analysis in a two-stage study. Model performance was assessed by calculating the area under the curve (AUC) and calibration analysis and compared with Nottingham Prognostic Index (NPI) and PREDICT. Results: Host characteristics were assessed for 10 809 women as the discovery population (median follow-up = 6.09 years, 1144 recurrence and 1627 deaths) and 4505 women as the validation population (median follow-up = 7.95 years, 684 recurrence and 1095 deaths). In addition to the known clinical/pathological variables, the model for recurrence included alcohol consumption while the model for OS included smoking status and physical component summary score. The AUCs for recurrence and OS were 0.813 and 0.810 in the discovery and 0.807 and 0.803 in the validation, respectively, compared with AUCs of 0.761 and 0.753 in discovery and 0.777 and 0.751 in validation for NPI. Our model further showed better calibration compared with PREDICT. We also developed race-specific and receptor subtype-specific models with comparable AUCs. Racial disparity was evident in the distributions of many risk factors and clinical presentation of the disease. Conclusions: Our integrative prognostic models for breast cancer exhibit high discriminatory accuracy and excellent calibration and are the first to incorporate receptor subtype and epidemiological and QoL data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.